New England Journal of Medicine· 2020Q1
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- 5,523citations
- Q1SCImago
- 2020year
Short summary
Lopinavir-ritonavir did not improve clinical outcomes or reduce mortality in hospitalized adults with severe COVID-19 compared to standard care alone.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Infectious Diseases
Infectious DiseasesMedicine